How to Sell a Substance Abuse Treatment Center in 2026

Selling a substance use disorder (SUD) treatment business is one of the most complicated transactions in healthcare M&A. You're selling a licensed, accredited, clinically regulated asset in an industry that still carries reputational scars from the Florida Shuffle era and the unethical marketing practices that triggered the Patient Brokering Act in 2018. Buyers are cautious, regulators are watching, and payers audit aggressively. If you run the process poorly, you won't get a close — you'll get a re-trade, a legal headache, or both.

That said, the buyer universe for well-run SUD platforms is strong. Summit BHC, Odyssey Behavioral Healthcare, BayMark Health Services, Discovery Behavioral Health, Pinnacle Treatment Centers, and Acadia Healthcare are all active acquirers, and several PE firms — Webster Equity, Bain Capital Double Impact, Trinity Hunt — have dedicated behavioral health theses. Done right, a $3-5M EBITDA SUD business trades at 7-10x EBITDA. Done wrong, it doesn't trade at all.

Accreditation Transfer Is Not Automatic

Every serious buyer will require you to hold Joint Commission or CARF accreditation, and every state license (residential, PHP, IOP, OTP if applicable) has its own change-of-ownership process. Neither transfers automatically at closing. This is the single biggest timing risk in an SUD transaction.

Start the CHOW paperwork early. California DHCS, Florida DCF, Pennsylvania DDAP, Texas HHSC — each state has different timelines, ranging from 60 days to 9 months. Some states require a new license application rather than a transfer, which means site surveys, staffing verification, and policy review. Buyers will structure closing in two steps: a sign-and-hold structure where the economics transfer at close but the licensed entity stays under seller control until the state approves the CHOW.

On accreditation: Joint Commission generally allows the existing accreditation to carry over for 30 days post-closing, after which the new owner must submit notice and typically undergo an unannounced survey within 12 months. CARF is similar. Document your last survey findings, any Requirements for Improvement (RFIs), and every corrective action plan. Buyers will want this on day one of diligence.

Payer Mix Drives Your Multiple

SUD valuations are almost entirely driven by payer mix. I've seen two facilities with nearly identical census and EBITDA trade at 5x and 10x because one was 70% out-of-network commercial and the other was 80% in-network commercial plus Medicaid.

Out-of-network business used to command premium rates — $1,500-$2,500 per day for residential, $400-$800 per day for PHP. Those days are over. UnitedHealthcare, Anthem, and Cigna have systematically narrowed networks, instituted aggressive utilization review, and pursued recoupment audits going back 2-3 years. If you're running an out-of-network model, buyers will assume the revenue isn't durable and discount accordingly.

In-network commercial contracts at sustainable rates — roughly $800-$1,200 for residential, $300-$500 for PHP, $150-$250 for IOP — are what buyers pay up for. Medicaid fee-for-service and managed Medicaid are also attractive if your state has favorable rates (think New York, Massachusetts, California). Pure self-pay models don't trade institutionally at all.

Regulatory Diligence Is Brutal

Expect a dedicated regulatory diligence workstream led by healthcare counsel. The buyer's firm — typically Ropes & Gray, McDermott Will & Emery, Polsinelli, or King & Spalding — will scrub the following:

• Marketing and patient brokering compliance. Every referral source, every lead generation contract, every call center arrangement. If you work with third-party marketers, expect invasive questions about payment structures. The Eliminating Kickbacks in Recovery Act (EKRA) criminalizes per-head referral payments even for commercially insured patients.
• 42 CFR Part 2 compliance. SUD records have special federal privacy protections beyond HIPAA. Document your consent forms, disclosure logs, and EHR configuration.
• Billing compliance. Urine drug testing practices, lab pass-throughs, telehealth billing, and group therapy billing are all common audit targets. If you have any history of payer recoupment, disclose it early.
• Lab ownership. If you own or have owned a toxicology lab, expect Stark and Anti-Kickback scrutiny. The DOJ has been aggressive on SUD lab arrangements since 2019.
• Clinical documentation. Treatment plans, individualized therapy notes, medical necessity documentation, discharge planning. Buyers will pull a chart sample and audit it.

If any of this makes you nervous, invest in a sell-side regulatory audit before you go to market. Firms like Polsinelli and Foley & Lardner do pre-transaction compliance reviews that identify issues you can remediate before buyers see them. The cost is $50-150K. The alternative is a re-trade or a broken deal.

What Buyers Pay For

Premium SUD multiples go to businesses with these characteristics: in-network commercial payer contracts, diversified payer mix with no single payer above 25% of revenue, stable 85%+ residential census utilization, multiple levels of care (residential plus PHP plus IOP) that enable internal step-downs, credentialed medical directors, and demonstrated clinical outcomes data.

The outcomes piece matters more than it used to. Buyers want to see your 30-day completion rates, readmission rates, and any outcomes tracking you do through platforms like Vista Research Group or OMNI Institute. If you have published outcomes or you participate in the ASAM outcomes registry, highlight it. Payers increasingly require it, and buyers know that.

Real estate matters too. If you own your residential facility, you can sell the operating business at a healthcare multiple and do a separate sale-leaseback at a real estate multiple — often a 15-20% total value pickup. Sale-leaseback buyers like Medical Properties Trust and regional healthcare REITs regularly play in SUD.

Running the Sale Process

Hire a specialist banker. This is not a sector for generalists. Firms that run SUD processes regularly include Provident Healthcare Partners, Cain Brothers, Coker Capital, and MHT Partners. They know which PE firms are actively deploying and which strategic buyers are in acquisition mode.

The process typically runs 8-12 months because regulatory diligence is slower than other healthcare sectors. Budget for sell-side quality of earnings, a regulatory pre-audit, and a clinical outcomes summary. Expect the buyer to require a 12-18 month transition services agreement and a 1-2 year earnout tied to census and payer contract retention.

Deal structures in SUD almost always include an EBITDA haircut for compliance risk. Even a clean business should expect the buyer to hold 5-10% of purchase price in escrow for 18-24 months against regulatory indemnification claims. Don't negotiate that away — buyers won't close without it, and fighting it signals you have something to hide.

What to Fix Before You Go to Market

If you're 12-18 months out from a sale, prioritize in this order:

Transition out-of-network revenue to in-network. It hurts current EBITDA but creates durable, predictable revenue that buyers will pay a higher multiple for. A 1x revenue haircut in the current year often translates to a 2-3x purchase price gain at exit.

Build real clinical leadership. Medical director, clinical director, and director of utilization review should be W-2 employees with contractual retention, not 1099 consultants. Buyers want to see that clinical oversight doesn't depend on the owner.

Document everything. Treatment plans, medical necessity notes, discharge summaries, UR documentation. If your EHR is KIPU, Sigmund, or BestNotes, run a sample audit across 50 charts and fix documentation gaps before they become diligence findings.

Sever any problematic marketing relationships. Call centers paid on a per-admit basis, lead generation firms with vague contracts, and referral arrangements that smell like kickbacks all need to be unwound well before you go to market. EKRA violations are criminal — buyers will walk the second their counsel sees an exposure.

Fix your census reporting. Every buyer will pull daily census by level of care for the trailing 24 months. If your EHR can't produce it cleanly, start working with your vendor now. Messy census data kills deals faster than any other operational issue.

The Bottom Line

SUD treatment businesses with clean compliance, in-network payer contracts, strong census, and a real continuum of care are selling at healthy multiples in 2026. Businesses with out-of-network billing models, messy marketing arrangements, or unresolved payer audits are not. The sellers who maximize value spend 12-18 months fixing compliance, diversifying payers, and documenting outcomes before engaging a banker. The ones who rush get broken deals.